Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence Abstract #2107

Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking
Aim(s): The aim was to provide real-life activity/efficacy/safety data on CB-ET in this setting
Materials and methods: Records of pts with advanced EP-PD-NEC (06/09-04/17) treated with CB-ET were retrospectively reviewed
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Melissa Frizziero

To read results and conclusion, please login ...

Further abstracts you may be interested in

#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Giovanni Paganelli
#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Maria Rosaria Ambrosio
#694 Platinum-Based Chemotherapy for the Treatment of High-Grade Gastrointestinal and Unknown Primary Neuroendocrine Neoplasms
Introduction: Poorly differentiated neuroendocrine carcinomas (NEC sec. WHO 2010) are rare and aggressive neoplasms arising from different districts throughout the body. Platinum and etoposide regimen has been the most widely used first line treatment in this setting.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Marco Paragona
#714 Oxalipatin-Based Chemotherapy for Grade 3 Neuroendocrine Carcinoma after Failure of Platinum- Based Chemotherapy
Introduction: Cisplatin/etoposide regimen is the recommended first line treatment for poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC). There is no standard second line.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Julien Hadoux
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.